Literature DB >> 32171680

Milan Interobserver Reproducibility Study (MIRST): Milan System 2018.

Daniel F I Kurtycz1, Ester Diana Rossi2, Zubair Baloch3, Derek Pavelec4, Emilio Madrigal5, Philippe Vielh6, William Faquin5.   

Abstract

INTRODUCTION: Prior to the 2018 publication of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC), a Web-based interobserver study was performed to evaluate MSRSGC reporting categories, identify cytomorphologic features that represent poor sources of agreement, and establish a baseline for future studies.
MATERIAL AND METHODS: Study participants evaluated 75 images chosen from the MSRSGC image set, prior to the release of the Milan Atlas. Images spanned all diagnostic categories including typical and borderline cytomorphology. Participant demographics were collected on level of training, practice patterns, and experience.
RESULTS: A total of 647 persons attempted access to the survey. Of these, 555 correctly answered the qualifying questions. Participants included: 16.5% ASCP Certified Cytotechnologists, 2.8% Specialist Cytotechnologists, 5.8% IAC Certified individuals, 14.3% Anatomic (AP) Certified Pathologists, 38.9% AP and Cytopathology Certified Pathologists, and 15.3% pathology trainees. Length of participant practice varied from 0 to 54 years. In our sample, 43.4% of participants came from academic centers, 17.6% from private hospitals; and 13.3% from commercial/private laboratories. Overall, 42% of respondents agreed with the reference interpretations of salivary gland lesions. The best agreement was seen in cytopathology certified pathologists. Among the MSRSGC categories, best agreement was found in Neoplasm-Benign (58.9%) and Non-Diagnostic (49.2%) categories, followed by Malignant (48.4%). The agreement rates for Salivary Gland Lesion of Uncertain Malignant Potential (SUMP) and Suspicious For Malignancy (SFM) were 23.6% and 22.7%, respectively.
CONCLUSIONS: Similar to the reproducibility studies conducted for gynecologic and urinary cytopathology, the most important factor in diagnostic reproducibility was a priori classification of image difficulty, although people with higher certifications performed better.
Copyright © 2020 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fine-needle aspiration; Interobserver reproducibility; Salivary gland cancer; Salivary gland cytology; Salivary gland neoplasm; The Milan System; Web-based image study

Mesh:

Year:  2020        PMID: 32171680      PMCID: PMC7404624          DOI: 10.1016/j.jasc.2019.12.002

Source DB:  PubMed          Journal:  J Am Soc Cytopathol        ISSN: 2213-2953


  15 in total

1.  Pitfalls in salivary gland fine-needle aspiration cytology: lessons from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology.

Authors:  Jonathan H Hughes; Emily E Volk; David C Wilbur
Journal:  Arch Pathol Lab Med       Date:  2005-01       Impact factor: 5.534

2.  The Milan System for Reporting Salivary Gland Cytopathology: Analysis and suggestions of initial survey.

Authors:  Esther Diana Rossi; William C Faquin; Zubair Baloch; Güliz A Barkan; Maria Pia Foschini; Marc Pusztaszeri; Philippe Vielh; Daniel F I Kurtycz
Journal:  Cancer Cytopathol       Date:  2017-07-14       Impact factor: 5.284

Review 3.  The Bethesda System for Reporting Cervical Cytology: A Historical Perspective.

Authors:  Ritu Nayar; David C Wilbur
Journal:  Acta Cytol       Date:  2017-07-11       Impact factor: 2.319

4.  Salivary gland tumor fine-needle aspiration cytology: a proposal for a risk stratification classification.

Authors:  Christopher C Griffith; Reetesh K Pai; Frank Schneider; Umamaheswar Duvvuri; Robert L Ferris; Jonas T Johnson; Raja R Seethala
Journal:  Am J Clin Pathol       Date:  2015-06       Impact factor: 2.493

Review 5.  Pitfalls of fine-needle aspiration cytology of parotid membranous basal cell adenoma-A review of pitfalls in FNA cytology of salivary gland neoplasms with basaloid cell features.

Authors:  Matthew Jurczyk; Joseph F Peevey; Mark A Vande Haar; Xiaoqi Lin
Journal:  Diagn Cytopathol       Date:  2014-11-27       Impact factor: 1.582

6.  Basal cell carcinoma metastatic to the salivary glands: differential diagnosis in fine-needle aspiration cytology.

Authors:  M W Stanley; C A Horwitz; R H Bardales; S J Stern; S Korourian
Journal:  Diagn Cytopathol       Date:  1997-03       Impact factor: 1.582

Review 7.  Fine-Needle Aspiration Biopsy of Salivary Gland Lesions.

Authors:  He Wang; Christopher Fundakowski; Jasvir S Khurana; Nirag Jhala
Journal:  Arch Pathol Lab Med       Date:  2015-12       Impact factor: 5.534

8.  Performance Characteristics of Adenoid Cystic Carcinoma of the Salivary Glands in Fine-Needle Aspirates: Results From the College of American Pathologists Nongynecologic Cytology Program.

Authors:  Z Laura Tabatabai; Manon Auger; Daniel F I Kurtycz; Alice Laser; Rhona J Souers; Rodolfo Laucirica; Guliz A Barkan; Barbara A Crothers; Walid E Khalbuss
Journal:  Arch Pathol Lab Med       Date:  2015-12       Impact factor: 5.534

9.  Going beyond "Basaloid neoplasm": Fine needle aspiration cytology of epithelial-myoepithelial carcinoma of the parotid gland.

Authors:  Stacy L Molnar; Matthew A Zarka; Luis E De Las Casas
Journal:  Diagn Cytopathol       Date:  2016-01-22       Impact factor: 1.582

10.  Moving Toward a Systematic Approach for Reporting Salivary Gland Cytopathology: An Institutional Experience and Literature Review.

Authors:  Xunda Luo; Nirag Jhala; Jasvir S Khurana; Christopher Fundakowski; Darshana N Jhala; He Wang
Journal:  Arch Pathol Lab Med       Date:  2018-07-25       Impact factor: 5.534

View more
  1 in total

1.  Putting morphology to the test: An established classification scheme reliably stratifies salivary gland cytology by risk of malignancy with substantial interobserver agreement.

Authors:  Daniel J Lubin; Christopher C Griffith; Darren J Buonocore; Xiao-Jun Wei; Oscar Lin
Journal:  Cancer Cytopathol       Date:  2020-11-02       Impact factor: 5.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.